FDA approves PDE-4 inhibitor for treating psoriatic arthritis

Apremilast, an oral phosphodiesterase-4 inhibitor, has been approved for treating adults with active psoriatic arthritis, based on the results of three studies of 1,493 patients, the Food and Drug...

Field of Interest: Rheumatology